Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 921-927

  Shirao, K ^a   Shimada, Y ^a   Kondo, H ^a   Saito, D ^a   Yamao, T ^a   Ono, H ^a   Yokoyama, T ^a   Fukuda, H ^a   Oka, M ^a   Watanabe, Y ^a   Ohtsu, A ^a   Boku, N ^a   Fujii, T ^a   Oda, Y ^a   Muro, K ^a   Yoshida, S ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA;

EID: 0031055829     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.921     Document Type: Article

References (45)

1. Moertel CG, Rubin J, O'Connell MJ, et al: A phase II study of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J Clin Oncol 4:1053-1057, 1986
2. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685-696, 1986
3. Preusser P, Wilke H, Achterrath W, et al: Phase II with the combination of etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310-1317, 1987
4. Wilke H, Preusser P, Fink U, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 7:1318-1326, 1989
5. Wilke H, Preusser P, Fink U, et al: New developments in the treatment of gastric carcinoma. Cancer Treat Res 55:363-373, 1991
6. Wils JA, Klein HO, Wagener DJT, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of gastric cancer: A trial of the EORTC. J Clin Oncol 9:827-831, 1991
7. Kelsen D, Atiq OT, Saltz L, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 10:541-548, 1992
8. Kim NK, Park YS, Heo DS, et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3918, 1993
9. Ohtsu A, Shimada Y, Yoshida S, et al: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 30A:2091-2093, 1994
10. Lacave AJ, Baron FJ, Anton LM, et al: Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A phase II trial. Ann Oncol 2:751-754, 1991
11. Wall ME, Wani MC, Cook CE, et al: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890, 1966
12. Moertel CG, Schutt AJ, Reitemeier RJ, et al: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101, 1972
13. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470, 1970
14. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
15. Andoh T, Ishii K, Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565-5569, 1987
16. Hsiang YH, Liu LF, Wall ME, et al: DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4835-4839, 1989
17. Matsuzaki T, Yokokura T, Mutai M, et al: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308-312, 1988
18. Tsuruo T, Matsuzaki T, Matsushita M, et al: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumor in vitro and vivo. Cancer Chemother Pharmacol 21:71-74, 1988
19. Chen AY, Yu C, Potmesil M, et al: Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039-6044, 1991
20. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990
21. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992
22. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
23. Noda K, Takeuchi S, Yakushiji M, et al: Late phase II study of CPT-11, new camptothecin derivative, in cervical and ovarian carcinoma. Proceedings of the 13th World Congress of Gynecology and Obstetrics (FIGO) 13:279, 1991 (abstr 0936)
24. Takeuchi S, Noda K, Yakushiji M, et al: Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 11:224, 1992 (abstr 708)
25. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
26. Kambe M, Wakui A, Nakao I, et al: A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers. Proc Am Soc Clin Oncol 12:198, 1993 (abstr 584)
27. Itoh K, Takada M, Kudo S, et al: Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines demonstrated by computer analysis. Lung Cancer 7:124, 1991 (abstr 459)
28. Kudoh S, Takada M, Masuda N, et al: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84:203-207, 1993
29. Minagawa Y, Kigawa J, Ishikawa H, et al: Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 85:966-971, 1994
30. Kondo H, Shimada Y, Shirao K, et al: Combination effects of CPT-11 and CDDP against human cell line: In vitro and in vivo examinations. Jpn J Cancer Res 85:616, 1994 (abstr 2241)
31. Masumoto N, Nakano S, Esaki T, et al: Inhibition of cisdiamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62:70-75, 1995
32. Masuda N, Fukuoka M, Takada M, et al: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780, 1992
33. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782, 1993
34. Sakata Y, Wakui A, Nakao I, et al: A late phase II study of irinotecan (CPT-11) in advanced pancreas cancer. Proc Am Soc Clin Oncol 12:211, 1993 (abstr 633)
35. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979
36. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma (English ed 1). Tokyo, Japan, Kanehara, 1995
37. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
38. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991
39. Rothenberg ML, Kuhn JB, Bums HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
40. de Forni M, Bugat R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354, 1994
41. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
42. Abigerges D, Chabot G, Armand J, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
43. Catimel G, Chabot GG, Guastalla JP. et al: Phase I and pharmacologic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6:133-140, 1995
44. Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972-974, 1992
45. Chabot GG, Abigerges D, Catimel G, et al: Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151, 1995